| Literature DB >> 27258357 |
Mokhtar R Gomaa1, Ahmed Kandeil1, Ahmed S Kayed1, Mona A Elabd1, Shaimaa A Zaki1, Dina Abu Zeid1, Amira S El Rifay1, Adel A Mousa2, Mohamed M Farag2, Pamela P McKenzie3, Richard J Webby3, Mohamed A Ali1, Ghazi Kayali3,4,5.
Abstract
Avian influenza viruses circulate widely in birds, with occasional human infections. Poultry-exposed individuals are considered to be at high risk of infection with avian influenza viruses due to frequent exposure to poultry. Some avian H7 viruses have occasionally been found to infect humans. Seroprevalence of neutralizing antibodies against influenza A/H7N7 virus among poultry-exposed and unexposed individuals in Egypt were assessed during a three-years prospective cohort study. The seroprevalence of antibodies (titer, ≥80) among exposed individuals was 0%, 1.9%, and 2.1% annually while the seroprevalence among the control group remained 0% as measured by virus microneutralization assay. We then confirmed our results using western blot and immunofluorescence assays. Although human infection with H7 in Egypt has not been reported yet, our results suggested that Egyptian poultry growers are exposed to avian H7 viruses. These findings highlight the need for surveillance in the people exposed to poultry to monitor the risk of zoonotic transmission of avian influenza viruses.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27258357 PMCID: PMC4892694 DOI: 10.1371/journal.pone.0155294
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Prevalence of anti-H7 antibodies among the study groups at different time points.
| Antibodies against H7 | Exposed Group, n (%) | Unexposed Group, n (%) |
|---|---|---|
| Positive at baseline | 0 (0%) | 0 (0.0%) |
| Negative at baseline | 565 (100%) | 150 (100%) |
| Positive at follow-up 1 | 13 (1.9%) | 0 (0%) |
| Negative at follow-up 1 | 669 (98.1%) | 139 (100%) |
| Positive at follow-up 2 | 14 (2.2%) | 0 (0%) |
| Negative at follow-up 2 | 635 (97.8%) | 104 (100%) |
Characteristics of A/H7sero-positive participants at study time points.
| Categories | Seropositive subjects at follow up 1 (n = 13); n(%) | Seropositive subjects at follow up 2 (n = 14); n(%) |
|---|---|---|
| Mean age(SD) | 23.15(19.8) | 28.5(15.24) |
| Median age | 17 | 23 |
| Age range | 5–49 | 6–63 |
| <6 years | 2 (15.38%) | 0(0.0%) |
| 6–16 years | 4 (30.8%) | 4(28.6%) |
| 17–50 years | 7 (53.82%) | 7(50%) |
| >51 years | 0(0.0%) | 3(21.45%) |
| Female | 10 (76.92%) | 8(57.2%) |
| Male | 3 (23.08%) | 6(42.9%) |
| Chronic lung problems | 0(0.0%) | 1(7.15%) |
| Cardiovascular problems | 0(0.0%) | 1(7.15%) |
| Other chronic problems | 1 (7.72%) | 0(0.0%) |
| Used tobacco products | 0(0.0%) | 1(7.15%) |
| Had ILI* within the preceding 12 months | 3(23.07) | 6(42.9%) |
| Household member had ILI | 4 (30.8%) | 4(28.6%) |
| Backyard exposure | 13(100%) | 14(100%) |
| Live bird market exposure | 5 (38.46%) | 3(21.45%) |
| Commercial farm exposure | 0(0.0%) | 0(0.0%) |
| Disease outbreaks in subject’s poultry | 6(46.15%) | 4(28.6%) |
| Ever received influenza vaccine | 0(0.0%) | 0(0.0%) |
| Vaccination of poultry | 1 (7.72%) | 1(7.15%) |
| Chickens at home | 12(92.3%) | 13(92.95%) |
| Chickens in neighborhood | 5 (38.46%) | 7(50%) |
| Live chickens in market | 4 (30.8%) | 2(14.3%) |
| Ducks at home | 3(23.07) | 7(50%) |
| Ducks in neighborhood | 0(0.0%) | 4(28.6%) |
| Live ducks in market | 0(0.0%) | 0(0.0%) |
| Geese at home | 3(23.07) | 4(28.6%) |
| Pigeons at home | 2 (15.38%) | 2(14.3%) |
| Turkeys at home | 2 (15.38%) | 0(0.0%) |
| Pet birds at home | 0(0.0%) | 0(0.0%) |
| Cats or dogs at home | 1 (7.72%) | 0(0.0%) |
| Cows or buffalo at home | 1 (7.72%) | 0(0.0%) |
| Goats at home | 1 (7.72%) | 2(14.3%) |
| Sheep at home | 0(0.0%) | 3(21.45%) |
| Other animals | 1 (7.7%) | 2(14.3%) |
| Pigs | 0(0.0%) | 0(0.0%) |
Demographic and serological profile of H7 sero-positivie subjects.
Antibody titers against H7 were tested using virus neutralization assay while antibodies against H1 and H3 were measured using hemagglutination inhibition assay.
| Subject ID | Age | Sex | Governorate | Household ID | Titer at Baseline | Titer at Follow up 1 | Titer at Follow up 2 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VMN titers against H7 | HI | HI titers against H3 | VMN titers against H7 | HI titers against H1 | HI titers against H3 | VMN titers against H7 | HI titers against H1 | HI titers against H3 | |||||
| 53 | 28 | F | Sharkiya | 10 | <10 | 4.3 | 4.3 | 10 | 3.3 | 1 | 80 | 8 | 1 |
| 57 | 31 | F | Sharkiya | 10 | <10 | 4.3 | 4.3 | 10 | 0 | 6 | 80 | 6 | 6 |
| 58 | 8 | F | Sharkiya | 10 | <10 | 4.3 | 4.3 | 20 | 0 | 7 | 80 | 8 | 7 |
| 93 | 8 | M | Sharkiya | 16 | <10 | 4.3 | 5.3 | 10 | 0 | 6 | 80 | 8 | 6 |
| 99 | 65 | M | Sharkiya | 17 | <10 | 4.3 | 4.3 | 10 | 3.3 | 4 | 80 | 6 | 4 |
| 103 | 60 | M | Sharkiya | 18 | <10 | N | N | 20 | 0 | 6 | 80 | 8 | 6 |
| 105 | 14 | M | Sharkiya | 18 | <10 | 4.3 | 7.3 | 20 | 0 | 5 | 80 | 8 | 4 |
| 114 | 21 | F | Sharkiya | 43 | <10 | N | N | 10 | 0 | 6 | 80 | 6 | 6 |
| 132 | 24 | F | Sharkiya | 48 | <10 | 4.3 | 5.3 | <10 | 0 | 5 | 80 | 6 | 4 |
| 133 | 30 | F | Sharkiya | 49 | <10 | 4.3 | 4.3 | 10 | 0 | 5 | 80 | 4 | 4 |
| 137 | 49 | F | Sharkiya | 53 | <10 | 4.3 | 7.3 | 10 | 0 | N | 80 | N | N |
| 142 | 11 | M | Sharkiya | 53 | <10 | 4.3 | 4.3 | 80 | 4.3 | 7 | 10 | 6 | 7 |
| 162 | 25 | F | Fayyoum | 64 | <10 | 4.3 | 4.3 | 20 | 3.3 | 6 | 80 | 4 | 6 |
| 205 | 8 | M | Fayyoum | 67 | <10 | N | N | 80 | 5.3 | 7 | <10 | 6 | 7 |
| 206 | 6 | F | Fayyoum | 67 | <10 | 4.3 | 7.3 | 80 | 5.3 | 7 | 40 | 8 | 7 |
| 207 | 10 | M | Fayyoum | 67 | <10 | 4.3 | 4.3 | 10 | 3.3 | 7 | 80 | 7 | 7 |
| 212 | 40 | F | Fayyoum | 77 | <10 | 4.3 | 6.3 | 80 | 3.3 | 8 | 40 | 7 | 8 |
| 214 | 13 | F | Fayyoum | 77 | <10 | 4.3 | 8.3 | 80 | 5.3 | 5 | 40 | 8 | 5 |
| 219 | 45 | F | Fayyoum | 78 | <10 | 4.3 | 4.3 | 80 | 0 | 6 | 40 | 7 | 6 |
| 225 | 18 | F | Fayyoum | 79 | <10 | 4.3 | 4.3 | 80 | 0 | 5 | 10 | 4 | 5 |
| 259 | 39 | F | Fayyoum | 87 | <10 | 4.3 | 4.3 | 80 | 0 | 6 | 20 | 4 | 6 |
| 271 | 51 | F | Fayyoum | 88 | <10 | 4.3 | 4.3 | 80 | 0 | 5 | 40 | 5 | 5 |
| 272 | 15 | M | Fayyoum | 76 | <10 | 4.3 | 4.3 | 80 | 0 | 7 | 10 | 5 | 7 |
| 369 | 21 | F | Gharbiya | 108 | <10 | 80 | 4.3 | 80 | 0 | 6 | 10 | 7 | 6 |
| 373 | 36 | F | Gharbiya | 108 | <10 | 160 | 4.3 | 80 | 6.3 | 7 | 40 | 6 | 7 |
| 472 | 18 | F | Qalyubiya | 119 | 10 | 4.3 | 5.3 | 80 | 5.3 | 6 | 20 | 5 | 6 |
| 559 | 58 | M | Qalyubiya | 131 | <10 | 4.3 | 4.3 | 10 | 0 | 4 | 80 | 6 | 4 |
*: Results reported in log2. N: Not Done
Fig 1Western blotting for H7 VMN positive sera and H7 seronegative sera against concentrated H7N7 virus.
All H7 positive sera were positive by western blot and immunogenic peptides were visualized at 67, 56–50, and 45 kDa corresponding to viral HA, NP/NA and HA1 respectively. The molecular weights of such peptides were estimated by including a low molecular weight protein marker (M) in the same run. VMN seronegative samples were also negative by western blotting. 1–4 show examples of positive human sera, 5–6 show negative human sera. Positive and negative H7N7 rat seraresults are shown on the left.
Fig 2Immunofluorescence (IF) assay for H7 VMN positive sera and H7 seronegative sera.
MDCK cells were inoculated with H7N7 virus then fixed and blocked by BSA. All sera that tested positive by VMN and 2 seronegative sera were diluted in blocking solution. FITC–conjugated goat anti–human IgG was then added. Fluorescently labeled cells were examined by fluorescence microscopy. Positive and negative control rat sera were tested and immunedetection was preformed using FITC–conjugated goat anti–rat IgG. An example of negative human sera (VMN titer <80) (A and B), negative rat sera (C), positive rat antisera (D), and positive human sera (VMN titer = 80) (E-L).